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Aim: To evaluate the effect of patient hematocrit on the measurement of pancreatitis
associated protein (PAP) from a dried blood spot specimen.
Methods: (1) All neonatal (<28 days old) hematocrit results were tabulated for 1
month (clinical lab database). (2) Newborns were retrospectively identiﬁed if dried
blood spots were obtained for newborn CF screening on more than one occasion
over a 1 year time frame. For each specimen, gestational age and post-natal ages
were collected. (3) A whole blood sample was spiked with PAP (0.1 ng/ml) and the
cell pack volume adjusted to achieve three aliquots containing hematocrits of 0.18,
0.40 and 0.59. These were then applied to Whatman 903 newborn screening cards.
The inﬂuence of hematocrit on the measurement of PAP (Dynabio PAP ELISA,
Marseille, France) was investigated.
Results: Hematocrit levels (mean±SD) for 0−6, 7−13, 14−20 and 21−27 days were
0.485±.085, 0.413±.079, 0.364±.071 and 0.336±.06, respectively (N= 608 for all
neonates <28 days old). A total of 16,074 neonates were screened for CF over
1 year with 205/16,074 (1.3%) neonates having more than one dried blood spot
collected. The mean age difference between sample collections was 19 days for
babies 25−29 weeks gestation to 11 days for babies 30−37 weeks gestation. PAP
concentrations detected were inversely affected by hematocrit with the lowest results
obtained from the specimen with the highest hematocrit (0.59).
Conclusions: (1) Hematocrit levels decrease signiﬁcantly during the ﬁrst four
weeks of life. (2) Repeat newborn sampling is rarely conducted within 7 days,
therefore hematocrit changes may need to be considered. (3) Hematocrit affects the
measurement of PAP from dried blood spots.
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Neonatal screening for Cystic Fibrosis (CF) enables children to be seen by specialist
CF Teams at the earliest opportunity, often when the child is asymptomatic. The
time of diagnosis is arguably one of the most important and distressing for a CF
family, with diagnosis being likened to bereavement. The early stage management
of CF is often focused on education and supporting the family.
We have developed a service over many years to aid the families through diagnosis,
however little is actually known of the parents’ experience. In order to understand
this area better and improve our service, an audit was commissioned for parents of
children diagnosed with CF between 2004–2006.
The audit questionnaire focused on initial diagnosis, the roles and attributes of the
CF team, and the quality and content of information. A sample of 19 was available
for the study, a good response of 13/19 (68%) was achieved.
The feedback given was that the approach to diagnosis was achieved well at
62% (8/13). 100% (13/13) thought the gradual introduction of the team worked
well. Improvements to contact details were suggested. 85% (11/13) had a high
level of conﬁdence in the team through accessibility of staff for clinic or home
visits and direct communication to all team members. 69% (9/13) felt the Team’s
communication skills were very effective and 69% (9/13) thought the information
that was provided by the team was very consistent.
We have found this audit beneﬁcial in re-designing our service. Suggested changes
were implemented for example; cough swab results are given whether positive or
negative.
